
Opinion|Podcasts|July 1, 2024
Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and DME
Listen
0:00 / 0:00
Key Takeaways
- Novel therapies, including targeted treatments and immunotherapy, have improved response rates and survival in lung cancer brain metastases.
- Advanced imaging techniques are essential for monitoring treatment efficacy and disease progression in patients.
A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.
Advertisement
1:12 Suboptimal Response
6:42 Treatment Strategy
11:22 Response to New Therapies
14:12 Imaging for Monitoring
18:42 Role of Ang-2
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy
2
Bimekizumab Data Support Case for Earlier Intervention in HS
3
A Genetic Signature May Predict Who Gets Sick From CAR T Cell Therapy
4
Rethinking HFpEF Screening and Care, With Ronald D'Agostino, DO
5







































































